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 Retina, a part of the central nervous system, serves as an
ideal model for elucidating molecular mechanisms underly-
ing complex neural functions of brain. The rod and cone pho-
toreceptors are sensory neurons that initiate a cascade of
phototransduction events to process visual signals in the retina
[1]. Neural retina leucine-zipper (NRL), a member of basic
motif leucine zipper (bZIP) family of DNA binding proteins,
is preferentially expressed in developing and mature-rod pho-
toreceptors and pineal gland [2-5]. It interacts with cone-rod
homeobox (CRX) and other transcriptional regulatory proteins
to activate the expression of most, if not all, rod photorecep-
tor genes [6-8]. NRL is critical for the differentiation of rod
photoreceptors; its loss leads to cone-only retina in mouse,
whereas ectopic expression of NRL converts cones to rods
[4,9,10]. Mutations in the human NRL gene are associated with
autosomal dominant retinitis pigmentosa (adRP) and other
retinopathies [11-14]. It has been suggested that disease-caus-
ing mutations alter the phosphorylation of NRL and conse-
quently affect its transcriptional regulatory function [11,14,15].
However, the precise biochemical mechanism(s) underlying
NRL phosphorylation and its effect on NRL activity have not
been delineated.
NRL belongs to Maf-oncogene subfamily and shares struc-
tural homology with Maf A, B, and c-Maf [16]. Previous stud-
ies have identified mitogen-activated protein kinases (MAPK)
that produce specific phosphorylation of Mafs and thus regu-
late transdifferentiation and stabilization of lens cells from
neuroretina [16,17]. In patients with adRP, similar conserved
phosphorylation sites are mutated in the NRL protein, sug-
gesting potential alteration of MAPK dependent phosphory-
lation of the protein in vivo [11,16]. A majority of NRL muta-
tions have been identified in the transactivation domain and
shown to alter synergistic activation of the rhodopsin promoter
in cultured cells [11,14,15]. Nonetheless, biochemical
mechanism(s) linking mutation-induced changes in the phos-
phorylation of NRL to signaling pathways associated with NRL
activity or NRL-mediated gene regulation have not yet been
reported.
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Purpose: Neural retina leucine-zipper (NRL), a member of the basic motif leucine zipper family of transcription factors,
is preferentially expressed in rod photoreceptors of the mammalian retina. Mutations in NRL are associated with retinopa-
thies; many of these are suggested to change phosphorylation status and alter NRL-mediated transactivation of rhodopsin
promoter. The purpose of this study was to identify potential kinases responsible for the phosphorylation of NRL and
determine if such kinase-dependent phosphorylation is altered in disease-associated NRL mutations.
Methods: Metabolic labeling with 33P-orthophosphate was used to study phosphorylation of NRL in transfected COS-1
cells. NRL or NRL mutants were expressed as glutathione S-transferase (GST)-fusion proteins and used as substrate to
screen various kinases by in vitro phosphorylation assays. CV-1 cells were co-transfected with rhodopsin promoter-re-
porter construct and expression plasmids, with or without specific mitogen-activated protein kinase (MAPK) inhibitors,
to examine their effect on NRL-mediated transactivation. Expression of activated MAPKs in postnatal mice retina was
determined by immunoblot analysis.
Results: Metabolic labeling of NRL produces multiple phosphorylated protein bands in transfected COS-1 cells. Fewer
but more intense radiolabeled bands are observed for NRL-S50T, -S50A, and -P51L mutants compared to wild-type NRL.
We show that MAPK2 and p38 induce specific phosphorylation of NRL, but this pattern is altered in NRL mutants.
Immunoblot analysis of extracts from developing mouse retina reveals enhanced expression of activated MAPK2 at
postnatal day 0-3, concordant with the reported phosphorylation pattern of NRL in vivo. Inhibition of MAPK signaling
pathways decreases NRL and CRX -mediated synergistic activation of rhodopsin promoter in transfected CV-1 cells.
Conclusions: Our results suggest that multiple MAPKs can phosphorylate NRL and this phosphorylation pattern is al-
tered by disease-associated NRL mutations. As inhibition of MAPK signaling pathways decreases NRL-mediated
transactivation of rhodopsin promoter, we propose that phosphorylation changes associated with NRL mutations perturb
gene expression in rods, leading to photoreceptor degeneration in retinopathies.
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1114In the current study, we performed metabolic phosphory-
lation of NRL to determine how mutations in NRL alter the
nature of phosphorylation and consequently its activity. We
have identified two MAPKs that produce specific phosphory-
lation of NRL. In corroborative experiments, we demonstrate
an increased level of activated MAPK2 in postnatal mouse
retina. We also report that disease-causing mutations alter
MAPK-dependent phosphorylation of NRL and affect
transactivation of rhodopsin promoter in transfected cells. Our
studies suggest a role of MAPK signaling pathways in influ-
encing NRL function during photoreceptor differentiation in
mammalian retina.
METHODS
Chemicals and reagents:  Reagents and chemicals were pur-
chased from New England Biolabs (NEB; Boston, MA) or
Roche Diagnostics (Munich, Germany). Phospho-MAPK2,
phospho-p38, protein kinase C (PKC) antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA), and
MAPK1/2 antibody was obtained from Sigma (St. Louis, MO).
The kinase inhibitors, U0126 and SB203580, were procured
from Promega, Madison, WI. Purified activated-MAPK2 was
obtained from NEB, whereas activated p38a was a gift from
Prof. A. Khattar, R R Laboratories (Delhi, India). Radioiso-
topes were procured from Board of Radiation and Isotope
Technology (Mumbai, India). All animal experiments in the
study were in accordance with the guidelines published by
Institute for laboratory animal research and performed after
due approval from institute animal ethics committee and
CPCSEA, India.
Expression constructs:  The prokaryotic expression con-
structs of NRL were generated in pGex4T-2 plasmid (GE Life
sciences, CT). The human NRL cDNA (AS321; [2]) was di-
gested with XcmI and HindIII to release the DNA fragment
containing the entire coding sequence of NRL. The fragment
was treated with T4-DNA polymerase and cloned at Sma I
restriction site of pGex4T-2 plasmid DNA. Various NRL-de-
letion constructs were produced by cloning PCR-amplified
NRL fragments that incorporated EcoRI or SmaI restriction
sites into pGex-4T-2 expression plasmid, which was digested
with appropriate restriction enzymes. Site-directed mutagen-
esis was used to generate different mutations in the NRL
(AS321, cDNA). The primer sets used to generate different
mutations in NRL are as follows:
NRL-S50A-sense 5'-GTG CCT CCT GCA CCC ACC
TTC AG-3' and antisense 5'-GGT GGG TGC AGG AGG CAC
TGA GCT G-3', NRL-P51L-sense 5'-GTG CCT CCT TCA
CTC ACC TTC AG-3' and antisense: 5'-GGT GAG TGA AGG
AGG CAC TGA GCT G-3', NRL-G122E-sense 5'-GAG ACA
GAA GCC CAG CAC GTC-3' and antisense 5'-GGG CTT
CTG TCT CCT CTG G-3'. The sequences of all expression
constructs were verified before undertaking any protein ex-
pression studies. The pEDNRL and pEDNRL-S50T expres-
sion constructs have been used previously [11]. Other con-
structs (pBR130, pcDNA-NRL, and pBCRX) used in the pro-
moter activation assays are described elsewhere [6,11,15].
Expression and purification of GST-fusion protein in E.
coli: The full-length, truncated or mutant NRL protein was
expressed as a fusion protein with GST in E. coli (BL21 strain).
GST-fusion protein was purified using glutathione-Sepharose
affinity chromatography, as described [18].
Transfection and metabolic labeling of the protein:  COS-
1 cells were transfected with a NRL-expression construct (7
mg) using DEAE-dextran method of transfection [3]. After 48
h, the transfected cells were incubated with methionine/phos-
phate-deprived media for an hour, before substituting with 35S-
methionine (200 mCi/ml) or 33P-orthophosphate (75 mCi/ml)
containing media for additional 3 h. Finally, radiolabeled cells
were washed three times in cold PBS, containing 1 mM Na-
orthovanadate, 1 mM NaF and protease inhibitors. Cells were
solubilized in radio-immunoprecipitation assay buffer and used
for immunoprecipitation assays. The radiolabeled proteins
were precipitated with specific antibodies, analyzed by SDS-
PAGE, and visualized by autoradiography.
Kinase-dependent phosphorylation assay:  Affinity-pu-
rified GST-NRL or mutant GST-fusion proteins were used to
perform activated kinase-dependent phosphorylation assays,
in vitro [18,19]. The bead-bound GST-fusion protein (4 mg)
was re-suspended in MAPK reaction buffer (50 mM Tris, pH
7.5, 10 mM MgCl2, 1 mM EGTA and 2 mM dithiothreitol),
and the reaction mixture was incubated for an hour at 30 °C
with 0.1 mCi of g32P-ATP (>6000 Ci/mmole) and 10 units of
purified activated MAPKs (MAPK2 or P38a). The bead-bound
proteins were washed three times in 10 mM Tris buffer, pH
7.5, containing 1 mM NaF and 1 mM sodium orthovanadate
and solubilized in 1X SDS-lysis buffer by heating for 3 min at
100 °C. The radiolabeled proteins were analyzed by SDS-
PAGE, followed by autoradiography. The radioactivity was
quantified by exposing gels to phosphor-imager screen, which
was scanned using Typhoon phosphor-imager scanner (GE
health sciences, Fairfield, CT). The specific activity of the
radiolabeled protein was estimated by normalizing the inten-
sity of radioactivity with the protein intensity, as measured
with Coomassie brilliant blue.
Immunoblot analysis:  Whole mouse retina was sonicated
in 10 mM Tris buffer, pH 7.5 containing protease inhibitors.
Retinal lysates (40 mg/lane) were separated on a 12% SDS-
PAGE for immunoblot analysis, as described [3].
Promoter activation assay:  To study the transactivation
function of NRL, we assayed the activity of rhodopsin pro-
moter in CV-1 cells by co-transfecting pBR130-luc plasmid
(luciferase reporter gene under the control of bovine rhodop-
sin promoter) with pCDNA-NRL, pBCRX, and pCMV-LacZ
constructs, as reported previously [11]. The transfection cock-
tail was prepared by mixing 150 ml of OptiMEM (Invitrogen)
with different plasmid DNAs (total 4.5 mg) to equal volume
of OptiMEM containing lipofectamine (4 ml/150 ml
OprtiMEM) at room temperature for 20 min. The transfection
cocktail was further diluted in OptiMEM, dispensed equally
in three separate cell culture wells and incubated for 5 h at 37
°C. The transfection cocktail was then substituted with com-
plete DMEM and incubated for additional 24 h under identi-
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1115cal cell culture conditions. At 36 h post-transfection, cells were
incubated with different MAPK kinase inhibitors (10-20 mmol)
for 12 h. The cells were then collected and solubilized in ap-
propriate lysis buffer for luciferase assays. Student’s t-test was
used to evaluate statistical significance between inhibitor-
treated and untreated samples.
RESULTS
Retinopathy-associated mutations alter metabolic phospho-
rylation of neural retina leucine-zipper in transfected COS-1
cells:  Ser-50 and Pro-51 mutations are shown to alter NRL
phosphorylation and NRL-mediated transactivation of rhodop-
sin minimal promoter in vitro [11,15]. However, direct evi-
dence supporting mutation-induced changes in NRL phospho-
rylation has not been reported. We therefore performed meta-
bolic phosphorylation of wild-type and mutant NRL in trans-
fected COS-1 cells. Labeled NRL protein was immunopre-
cipitated and analyzed by SDS-PAGE, followed by autorad-
iography (Figure 1). Only two major radiolabeled bands were
detected for NRL-S50T, -S50A, and -P51L compared to more
than six bands for the control NRL and NRL-G122E (a non-
pathogenic variant; Figure 1). However, the amount of radio-
activity detected for NRL-S50T, -S50A, and -P51L was much
higher than the radiolabeled bands observed in control. To
examine any possible adverse effect of the mutations on NRL
expression, NRL constructs were also transfected in COS-1
cells in presence of 35S-methionine. Analysis of the radiola-
beled proteins showed that the cumulative intensity of 35S-
labeled proteins obtained with control and mutant NRL con-
structs (except NRL-G122E) was fairly similar (Figure 1B).
However, the specific bands of 28-30 kDa identified in NRL-
S50T, -S50A and -P51L had enhanced 35S-methionine label-
ing compared to corresponding bands (of 28-30 kDa) in con-
trol. The mutant NRL protein bands (of 28-30 kDa) that showed
enhanced incorporation of 35S-methionine also produced an
equivalent increase in 33P incorporation in the metabolic phos-
phorylation studies (Figure 1A,B).
Neural retina leucine-zipper-mutations associated with
autosomal dominant retinitis pigmentosa alter mitogen-acti-
vated protein kinases-dependent phosphorylation:  In order
to identify the kinases, full-length and truncated NRL were
expressed as GST-fusion proteins (Figure 2A) and used as sub-
strate for purified activated MAPK2 and p38a in kinase-de-
pendent phosphorylation assays, in vitro. Activated MAPK2
produced specific phosphorylation of GST-NRL, GST-NRL-
N80 (with amino terminal 80 amino acids of NRL) and GST-
NRL-N144 (with amino terminal 144 amino acids of NRL),
but failed to phosphorylate GSTDNRL (with carboxyl termi-
nal 110 amino acids of NRL) and GST (Figure 2B). On the
other hand, activated p38a was able to specifically phospho-
rylate full-length and almost all NRL-truncations, including
GST-DNRL, in an identical phosphorylation assay in vitro
(Figure 2C). These results suggest that phosphorylation sites
specific to activated MAPK2 are confined to the amino-ter-
minal half of NRL, whereas activated p38a recognizes mul-
tiple phosphorylation sites throughout the NRL protein.
To evaluate whether mutations in NRL affect MAPK-de-
pendent phosphorylation of the protein, we used GST-NRL
mutants as substrate for kinase-dependent phosphorylation as-
says, in vitro. Analysis of the radiolabeled proteins indicated
that the phosphorylation induced by activated MAPK2 was
decreased in GST-NRL-S50T and -P51L mutants compared
to the wild-type control (Figure 2D), whereas activated p38a
produced enhanced phosphorylation of the GST-NRL-S50T
and -P51L mutants (Figure 2E). Purified GST was used as a
negative control for phosphorylation assays (Figure 2B-E).
Quantification of the specific radioactivity indicated that acti-
vated MAPK2 induced 59% decrease in the phosphorylation
of GST-NRL-P51L, in contrast to 57% increase in the phos-
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Figure 1. Mutation alters metabolic phosphorylation of neural retina
leucine-zipper in transfected COS-1 cells.  COS-1 cells transfected
with different expression plasmids were radiolabeled with either (A),
33P-Orthophosphate; or (B), 35S-Methionine in vitro. COS cell ly-
sates transfected with: Lane 1, pED; lane 2, pEDNRL; lane 3,
pEDNRL-S50T; lane 4, pEDNRL-G122E; lane 5, pEDNRL-P51L;
lane 6, pEDNRL-S50A were immunoprecipitated using anti-NRL
antibody and used equal amount of the total protein to analyze by
SDS-PAGE followed by autoradiography. In the figure, NRL-G122E
observed to be a non-pathogenic, sporadic mutation in the affected
patient was used as a second control in the analysis.
1116phorylation by activated p38a compared to respective con-
trols (Figure 2F). Identical changes were observed in case of
GST-NRL-S50T, but the level of phosphorylation was inter-
mediate to that observed for GST-NRL-P51L and NRL-con-
trols (Figure 2F). The data suggest that mutations induce dif-
ferential phosphorylation of the mutant NRL by activated
MAPK2 and p38a.
Higher levels of activated mitogen-activated protein ki-
nase-2 are expressed in early postnatal mouse retina:  In mouse
retina, multiple phospho-isoforms of NRL are detected as early
as postnatal (PN) 2 during development [3]. To determine
whether levels of activated MAPK2 expressed in retina coin-
cide with the appearance of NRL phospho-isoforms, total reti-
nal proteins from different postnatal stages of mice were sub-
jected to immunoblot analysis using anti-MAPK antibodies.
Enhanced expression of activated (phospho)-MAPK2 was
observed in PN 0-3 retina, and this came back to a basal level
at and after PN 4 (Figure 3A). However, the levels of MAPK1/
2 (un-phosphorylated) expression remained unchanged
throughout the entire first postnatal week of retinal develop-
ment (Figure 3B). All immunoblots were re-probed with anti-
b-tubulin antibody as an internal standard to normalize the
amount of total retinal protein (Figure 3C).
Inhibition of mitogen-activated protein kinases signaling
affects NRL-mediated transactivation of rhodopsin promoter
in vitro:  The activation of rhodopsin minimal promoter has
been used as a functional assay to demonstrate NRL-medi-
ated transcription of retinal genes in vitro [11,15]. To deter-
mine the effect of MAPK signaling pathways, COS-1 cells
were co-transfected with rhodopsin promoter construct and
plasmids expressing different activator proteins (NRL and
CRX), and treated with or without specific MAPKs inhibi-
tors, U0126 or SB203580 [20,21]. The amount of luciferase
activity was normalized against b-galactosidase to derive the
relative light units used as a measure of promoter activity (Fig-
ure 4). In cells co-transfected with either NRL or CRX, the
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Figure 2. MAPKs produce differential phosphorylation of neural retina leucine-zipper and mutated neural retina leucine-zipper in vitro.  A:
Schematic representation of full length and truncated NRL expressed as GST-fusion protein and used as substrate in the phosphorylation
assays. GST-NRL represents the fusion protein expressing the full length NRL; GST-DNRL, with carboxyl terminal 110 amino acids; GST-
NRL-N144, with amino terminal 144 amino acids and GST-NRL-N80, with amino terminal 80 amino acids of NRL, respectively. Kinase-
dependent phosphorylation assays were performed to phosphorylate full length and truncated GST-NRL using either (B) purified activated
MAPK2 or (C) activated p38a in vitro. Radiolabeled proteins: Lane 1, GST; lane 2, GST-NRL; lane 3, GST-DNRL; lane 4, GST-NRL-N144;
lane 5, GST-NRL-N80 were analyzed by SDS-PAGE followed by autoradiography. In similar studies, either (D) activated MAPK2 or (E)
activated p38a was used to phosphorylate GST-NRL with or without specific mutations in vitro. Radiolabed samples analyzed by SDS-PAGE
followed by autoradiography includes: Lane1, GST; lane 2, GST-NRL; lane 3, GST-NRL-S50T, lane 4, GST-NRL-P51L in the phosphoryla-
tion assay. The specific radioactivity of the protein was estimated by normalizing radioactivity with intensity of the corresponding protein
band stained with Coomassie brilliant blue. (F) Three independent experiments phosphorylated using similar conditions were used to estimate
the relative changes in the radioactivity of the protein. Error bars represent the standard deviation, n=3 in the histogram.
1117treatment with U0126 produced lesser transactivation of the
rhodopsin promoter compared to the control (i.e., cells treated
with DMSO alone). The cells transfected with NRL alone and
treated with SB203580 failed to produce any significant change
in the activation of rhodopsin promoter compared to control.
However, the cells co-transfected with both NRL and CRX
and treated with either U0126 or SB203580 produced signifi-
cantly less synergistic activation of the rhodopsin proximal
promoter compared to the control cells without inhibitors (Fig-
ure 4). In a separate experiment, lithium chloride (an inhibitor
of GSK3 activation pathway) was used to test whether signal-
ing pathways other than MAPKs produced any significant
change in the NRL-mediated transactivation of the rhodopsin
promoter (data not shown). Taken together, the results sug-
gest that MAPK-dependent signaling pathways influence
NRL-mediated gene regulation in vitro.
DISCUSSION
 Phosphorylation and dephosphorylation of proteins play criti-
cal roles in mediating the dynamics of signaling pathways in
living cells. NRL is a phospho-protein that performs critical
roles during photoreceptor differentiation in mammalian retina
[3-5,10]. In this report, we have identified two MAPKs (acti-
vated MAPK2 and p38a) that produce specific phosphoryla-
tion of NRL, in vitro. Using site-specific mutations and trun-
cated forms of NRL, we demonstrate that a majority of acti-
vated MAPK2-dependent phosphorylation sites of NRL are
confined to the amino-terminal half of the protein. Activated
MAPK can also phosphorylate similar conserved sites in the
amino-terminal region of the homologous Maf proteins in vitro
[16]. Using separate kinase-dependent phosphorylation stud-
ies, we show that adRP-associated S50T and P51L mutations
decrease the phosphorylation of mutant NRL protein by acti-
vated MAPK2. Interestingly, both of these representative
mutations that induce decreased activated MAPK2-mediated
phosphorylation are present in the transactivation domain of
NRL.
In consensus MAPK-dependent phosphorylation sites,
proline is a key residue of the signature sequences [22]. The
Pro-51 residue in the transactivation domain of NRL is part of
the consensus MAPK-recognition sequence as P51L mutation
resulted in reduced phosphorylation by activated MAPK2 in
vitro. Our data reveals the role of NRL Pro-51 as an authentic
MAPK2-dependent phosphorylation site, which when mutated
in retinopathy patients affects the downstream transcriptional
regulatory functions of NRL [12-14]. Notably, the mutation at
the phospho-amino acid, Ser-50, produces a modest decrease
in phosphorylation by activated MAPK2. The phosphoryla-
tion studies, reported here, also indicate multiple MAPK sites
that contribute to phosphorylation of NRL. We suggest that
multiple phospho-isoforms of NRL observed in the retina or
in transfected cells are the result of cumulative phosphoryla-
tions that are mediated by distinct ubiquitously-expressed ki-
nases [3]. It is also evident that mutations at any single site of
NRL are not sufficient to completely eliminate the phospho-
rylation of the protein.
Both NRL-P51L and -S50T mutations involve a single
consensus phosphorylation site in the transactivation domain
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Figure 3. Mitogen-activated protein kinase expression studies in post-
natal mouse retina.  Postnatal mice retina obtained at: Lane1, (PN)
day 0; lane 2, PN 1; lane 3, PN 2; lane 4, PN 3; lane 5, PN 4; lane 6,
PN 5, and lane 7, PN 7 were subjected to immunoblot analysis by
probing with specific antibodies: A, anti-Phospho-MAPK2; B, anti-
MAPK1/2; and C, anti-βTubulin antibodies. The intensity of the
immunolabeled bands is directly proportional to the level of specific
protein expressed in the retinal samples. Intensity of b-tubulin was
used as internal control to normalize the total protein used for analy-
sis.
Figure 4. Inhibition of mitogen-activated protein kinase pathways
affects neural retina leucine-zipper-mediated transactivation of
rhodopsin minimal promoter in transfected CV-1 cells.  CV-1 cells
were co-transfected with NRL, CRX, or combination of both to
transactivate bovine rhodopsin minimal promoter (BR130-luc) in
vitro. Luciferase expressed in each reaction condition was normal-
ized with the corresponding amount of b-galactosidase and repre-
sented as relative light unit in the histogram. The DMSO treated
samples are represented as, black bar and treated as control in the
experiment. Whereas, samples treated with kinase inhibitor, U0126
and SB203580 represented as shaded white and shaded brown, re-
spectively. Data from three independent experiments were used to
calculate mean and standard error for each experimental condition
and students’ t-test was used to determine the statistical significance
between different treatment groups. Values marked with * represents
statistically significant at p<0.001 in the analysis.
1118of NRL. Though in silico analysis did not predict any poten-
tial p38a phosphorylation sites in this particular region, both
NRL-S50T and P51L mutants produce enhanced phosphory-
lation by activated p38a in the in vitro assay. We propose that
mutations in the transactivation domain of NRL alter the con-
formation of the protein and expose few uncommon phospho-
rylation sites, which may otherwise be hidden or less avail-
able for active phosphorylation by p38a in the native protein.
The two MAPKs identified here are expressed ubiqui-
tously, consistent with previous reports showing that the pro-
file of NRL phospho-isoforms expressed in COS-1 cells is
similar to those detected in the native retina tissue [3,15]. We
demonstrate by metabolic phosphorylation studies that muta-
tions in NRL alter cumulative phosphorylation of the protein
in vitro. In case of NRL-S50T, -S50A, and -P51L, the par-
tially de-phosphorylated isoforms of NRL are accumulated to
form two major bands that show enhanced radiolabeling of
both 33P and 35S-methionine, representing phosphorylation and
total protein content, respectively. However, NRL-G122E,
which is likely to be a polymorphism fails to produce any
significant change in the phosphorylation of the protein Mul-
tiple MAPK sites in the transactivation domain of NRL iden-
tify it as a phosphorylation hot spot, which is consistent with
the prevalence of retinopathy mutations in this region. Simi-
lar sites in Maf A and B are also phosphorylated by activated
MAPKs [16,17]. Notably, activated p38 is reported to phos-
phorylate Maf proteins, in vitro [23], and p38-mediated phos-
phorylation can regulate proliferation and differentiation of
neuronal cells in brain [24-26] and cell cycle progression of
neuroblastic cells in postnatal rat retina [27].
Our immunoblot analysis showing increased level of ac-
tivated MAPKs in mouse retina during postnatal day 0-3 is of
interest as this is the peak period of rod photoreceptor birth
[5,28]. Immunolocalization studies indicate that rod precur-
sors co-express both activated MAPK2 and NRL before the
expression of rhodopsin and the lamination and formation of
distinct neuronal layers in the retina (data not shown). The
higher expression of activated MAPK2 at PN 0-3 is concor-
dant with the reported expression of Nrl phospho-isoforms in
vivo [3]. We therefore propose that activated MAPK2 con-
tributes to the phosphorylation of NRL and consequently gene
regulation during rod differentiation.
Growth factors promote differentiation and survival of
photoreceptors through the activation of MAPK pathways [29].
Identification of NRL as a downstream substrate of MAPK-
regulated pathways provides a possible mechanism of how
growth factors exert this control. The observation that inhibi-
tion of MAPK pathways by treatment with U0126 or
SB203580 affects NRL-mediated transactivation of rhodop-
sin promoter supports this hypothesis. However, decreased
transactivation of rhodopsin promoter due to the involvement
of signaling cross-talk and role of other potential phospho-
proteins within the rhodopsin transcription complex can not
be ruled out in current studies.
In conclusion, we have identified NRL as an important
substrate of MAPKs. NRL phosphorylation by multiple
MAPKs makes it an important cellular target for integrating
various signaling pathways to regulate gene expression in de-
veloping and mature retina.
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